Oncotarget is a medical journal published by Impact Media on research results regarding topics such as oncology, neuroscience, metabolism, cardiology, cell biology, endocrinology, and pharmacology among others. Its chief editors are Andrei. V Gudkov from Roswell Park Cancer Institute and Mikhail Blagosklonny, who is among the top researchers in the field of cancer.
History of the Oncotarget Journal
The current multidisciplinary journal was first published in 2010 as an oncology journal, specializing in the study of control, treatment, and development of tumors. Due to its multi-peer review and constructiveness of its research results, the journal became popular and successful. This raised the necessity for expansion thus the change from an oncology journal to a multidisciplinary journal covering all the sectors in medicine.By 2016, Oncotarget had made an average impact of about 5.168 as stated by Journal Citation Report. Oncotarget began as a weekly journal but due to its high public demand, it is currently published twice a week; both on Tuesday and Friday. Its great success and impact is due to its proactive editors, authors, and publisher.
Purpose of the Journal
The ultimate goal of the privately owned journal is to provide quick research results in medicine and involve everyone in the progression of science. By providing medical research results in all fields of human biology, it is possible for scientists to relate them and come up with possible treatment and control for complex diseases such as cancer.Oncotarget offers free access which enables readers to download, print, distribute, or modify the articles. This makes the journal available to a wide range of readers. Availing these medical research results saves the time scientists spent during research and also informs them of new exceptional discoveries or advancements in the field of medicine. Being a multidisciplinary journal, its goal is to bridge the gap between specialties and encourage comprehensive study of medicine.
Oncotarget and IntegraGen
IntegraGen, a company that specializes in converting biological samples’ information into genomic information and tools for diagnosis of oncology, announced that its test would be published on Oncotarget. The test is called `miRpredX 31-3p’ and is the first successful test for metastatic colorectal cancer patients.Oncotarget as a business is determined in publishing outstanding research and applying all the necessary security policies such as editorial, license, peer-review, and publishing policies. Its chief-editors and authors ensure the journal is ready in time and with constructive information to meet the standards of the readers. The journal has made a great impact in fostering the application of clinical and basic science in fighting diseases.